Heather M. Scobie

Heather M. Scobie

Auto-generated profile, based on publicly available information

Heather M. Scobie

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
HSHeather M. Scobie
Heather M. Scobie
AJAmelia G. Johnson
Amelia G. Johnson
ASAmitabh B. Suthar
Amitabh B. Suthar
RSRachel Severson
Rachel Severson
NANisha B. Alden
Nisha B. Alden
BSBenjamin J. Silk
Benjamin J. Silk
After the COVID-19 B.1.617.2 (Delta) variant reached predominance, fully vaccinated people had less risk of infection, hospitalization, and death.

1 October 2020 in Vaccine
Verified
Journal Article
Open access
HSHeather M. Scobie
Heather M. Scobie
MEMichael Edelstein
Michael Edelstein
ENEdward Nicol
Edward Nicol
AMAna Morice
Ana Morice
NRNargis Rahimi
Nargis Rahimi
JJJaleela Jawad
Jaleela Jawad
• Reported to SAGE on immunization and surveillance data quality & use, October 2019. • Improvements since 2011, but gaps persist in data quality (fit-for-purpose) and use. • Improving data quality and use requires better governance, people, tools, and processes. • Better use of existing data needed to continuously improve programme performance. • Report relevant for “data-guided” implementation of the Immunization Agenda 2030.

1 July 2016 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
HSHeather M. Scobie
Heather M. Scobie
BMBunsoth Mao
Bunsoth Mao
SBSokhal Buth
Sokhal Buth
KWKathleen A. Wannemuehler
Kathleen A. Wannemuehler
CSCharlotte Sørensen
Charlotte Sørensen
CGChristopher J. Gregory
Christopher J. Gregory
To monitor progress toward maternal and neonatal tetanus elimination (MNTE) in Cambodia, we conducted a nationwide serosurvey of tetanus immunity in 2012. Multistage cluster sampling was used to select 2,154 women aged 15 to 39 years. Tetanus toxoid antibodies in serum samples were measured by gold-standard double-antigen enzyme-linked immunosorbent assay (DAE) and a novel multiplex bead assay (MBA). Antibody concentrations of ≥0.01 IU/ml by DAE or the equivalent for MBA were considered seroprotective. Estimated tetanus seroprotection was 88% (95% confidence interval [CI], 86 to 89%); 64% (95% CI, 61 to 67%) of women had antibody levels of ≥1.0 IU/ml. Seroprotection was significantly lower ( P < 0.001) among women aged 15 to 19 years (63%) and 20 to 24 years (87%) than among those aged ≥25 years (96%), among nulliparous women than among parous women (71 versus 97%), and among those living in the western region than among those living in other regions (82 versus 89%). The MBA showed high sensitivity (99% [95% CI, 98 to 99%]) and specificity (92% [95% CI, 88 to 95%]) compared with DAE. Findings were compatible with MNTE in Cambodia (≥80% protection). Tetanus immunity gaps should be addressed through strengthened routine immunization and targeted vaccination campaigns. Incorporating tetanus testing in national serosurveys using MBAs, which can measure immunity to multiple pathogens simultaneously, may be beneficial for monitoring MNTE.

12 May 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
HSHeather M. Scobie
Heather M. Scobie
MPMark Panaggio
Mark Panaggio
ABAlison M. Binder
Alison M. Binder
MGMolly E. Gallagher
Molly E. Gallagher
WDWilliam M. Duck
William M. Duck
BSBenjamin J. Silk
Benjamin J. Silk
This report describes an evaluation of national COVID-19 surveillance data sources and indicators for ongoing monitoring.

4 June 2014 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
HSHeather M. Scobie
Heather M. Scobie
Eric James NillesEric James Nilles
Eric James Nilles
MKMike Kama
Mike Kama
JKJacob L. Kool
Jacob L. Kool
EMEric Mintz
Eric Mintz
KDKashmira Date
Kashmira Date
After a category 4 cyclone that caused extensive population displacement and damage to water and sanitation infrastructure in Fiji in March 2010, a typhoid vaccination campaign was conducted as part of the post-disaster response. During June–December 2010, 64,015 doses of typhoid Vi polysaccharide vaccine were administered to persons ≥ 2 years of age, primarily in cyclone-affected areas that were typhoid endemic. Annual typhoid fever incidence decreased during the post-campaign year (2011) relative to preceding years (2008–2009) in three subdivisions where a large proportion of the population was vaccinated (incidence rate ratios and 95% confidence intervals: 0.23, 0.13–0.41; 0.24, 0.14–0.41; 0.58, 0.40–0.86), and increased or remained unchanged in 12 subdivisions where little to no vaccination occurred. Vaccination played a role in reducing typhoid fever incidence in high-incidence areas after a disaster and should be considered in endemic settings, along with comprehensive control measures, as recommended by the World Health Organization.

8 February 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
HSHeather M. Scobie
Heather M. Scobie
MPMinal Patel
Minal Patel
DMDiana Martin
Diana Martin
HMHarran Mkocha
Harran Mkocha
SNSammy M. Njenga
Sammy M. Njenga
PLPatrick J. Lammie
Patrick J. Lammie
Recent tetanus cases associated with male circumcision in Eastern and Southern Africa (ESA) prompted an examination of tetanus immunity by age and sex using multiplex serologic data from community surveys in three ESA countries during 2012–2013. Tetanus seroprotection was lower among children 5–14 years versus 1–4 years of age in Kenya (66% versus 90%) and Tanzania (66% versus 89%), but not in Mozambique (91% versus 88%), where children receive two booster doses in school. Among males ≥ 15 years of age, tetanus seroprotection was lower than females in Kenya (45% versus 96%), Tanzania (28% versus 94%), and Mozambique (64% versus 90%). Tetanus immunity from infant vaccination doses wanes over time, and only women of reproductive age routinely receive booster doses. To prevent immunity gaps in older children, adolescents, and adult men, a life-course vaccination strategy is needed to provide the three recommended tetanus booster doses.